Re: Vorlon, you will be still optimistic and expect BP deals even if they file BK tomorrow. EOM
My point was a reply to a comment by canis star who said if the company went under that I would think the IP still had value. So I wish to clarify. If the USA government went bankrupt....does the gold in Fort Knox still have value? That is what I was trying to imply. Our IP on our drug does amazing stuff. Regardless of mgts ability to make the company continue....the IP still has value. At this moment in time, until a better primer comes along with just as safe lack of side effects....the IP has value.
That IP value is going up with the addition of a new drug application in blood cancers as Poetic figured out something entirely new on how to use PV-10 to treat leukemia. I did not predict this at all. We are getting a new drug with brand new patent.
Now an independent group is also investigating on their own dime new antiviral properties of either PH-10 or PV-10..... interleukin inhibitor properties and other paths never thought possible before as an anti-viral. This is new to me as well. This new research was derived from PH-10 data. They saw something PVCT did not...and now they are running with it ASAP. More patents likely coming with that independent research firm likely as co-patents. Being on their dime I assume a split of the global market for any outcome that may end up becoming a market....as their payment for the research. What they found might end up as a brand new path of anti viral therapy. Intriguing.
Now to look forward on timing. By next April all combo P1 trials are scheduled to finish at near a point to assemble all P1combo data in time for ASCO first week of June. Shortly thereafter all ratchet warrants expire...just before next annual meeting where all PHR liens come off.....if I got that timing correct....correct me if Iím wrong. At the next annual meeting the poison pill comes off....opening up life science investment firms and hedge funds to take over the company if they so choose to do so. Am I wrong?
So for current mgt....the window to make a codevelopment deal at a minimum is set. Do you see this now? Do you see why itís now necessary to pad the uveal P1 with more patients with triple combo BMY drugs while reporting on combos using Merckís drugs in the other trials? On top of this remember Pfizer still co-patent owner on single combo. Mgt has three big pharmas tied into future P1 combo and triple combo results.
As a result...while Wall Street remains clueless on the real science of cascade priming from the very beginning....I will continue to add to my position. What I see as a clear path playing out...I do get frustrated at times with shareholders. The bitching of some..,.the addition on this board of things that donít really matter to this research....causes me from time to time to lose my cool. And while I initially got an education start years ago from Dr.Dees on the initial science....(five nights a week for 6-8 hours a night ...for seven years straight)..,I spent an incredible effort on tying research on all platforms together. For those that take offense at my outbursts from time to time....I would have done exactly the same in conversation if you were in front of me. To me this board is a debate. Since you are not in front of me, my responses may seem harsh. To me, Iím just trying steer the conversation to my points. I will continue to debate my thoughts and positions.